Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical ALA Penetration in Skin Cancer
NCT00002963Phase 2
Key facts
- Status
- Completed
- Start
- Nov 1993
- Primary completion
- Jun 2007
- Countries
- 1
- Modality
- Small Molecules
- Conditions
- basal cell carcinoma (BCC)squamous cell carcinoma (SCC)
01
Overview
Phase 2, randomised, open-label trial of 5-aminolevulinic acid in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) (2 arms), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Depth of penetration of aminolevulinic acid. Started Nov 1993; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
4-5 Hour Application
Topical ALA applied for 4-5 hours
20-24 Hour Application
Topical ALA applied for 20-24 hours
03
Endpoints
Primary
Depth of penetration of aminolevulinic acid
Secondary
Depth of fluorescence
Comparison of tissue fluorescence with surface fluorescence
Beyond the preview
Go deeper on NCT00002963.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002963.